open access

Vol 8, No 5 (2012)
Review paper
Published online: 2012-11-27
Get Citation

Crizotinib — a new molecular targeted agent in the treatment of non-small-cell lung cancer

Rafał Czyżykowski, Sylwia Dębska, Maja Habib, Magdalena Krakowska, Joanna Kubicka, Piotr Potemski
Onkol. Prak. Klin 2012;8(5):193-203.

open access

Vol 8, No 5 (2012)
REVIEW ARTICLES
Published online: 2012-11-27

Abstract

Non-small cellular lung cancer (NSCLC) represents heterogeneous group of neoplasms with diversity of
histopathological, molecular profile and various clinical course. Progress in the field of molecular biology,
which has taken place during last years, enabled identification of potential oncogenic pathways. ALK
mutations are rare and can be found in approximately 5% of patients with the diagnosis of NSCLC. They
are more common in young, non-smoking men with adenocarcinoma. Crizotinib is an ATP-competitive,
orally bioavailable ALK inhibitor and was approved by FDA in August 2011 for treatment of patients with
locally advanced or metastatic ALK-positive NSCLC. Phase I and II trials revealed promising results. Treatment
with crizotinib was associated with 62% of objective response rate in molecularly defined subgroup
of patients. Final conclusions are subject to further III phase clinical trials.

Abstract

Non-small cellular lung cancer (NSCLC) represents heterogeneous group of neoplasms with diversity of
histopathological, molecular profile and various clinical course. Progress in the field of molecular biology,
which has taken place during last years, enabled identification of potential oncogenic pathways. ALK
mutations are rare and can be found in approximately 5% of patients with the diagnosis of NSCLC. They
are more common in young, non-smoking men with adenocarcinoma. Crizotinib is an ATP-competitive,
orally bioavailable ALK inhibitor and was approved by FDA in August 2011 for treatment of patients with
locally advanced or metastatic ALK-positive NSCLC. Phase I and II trials revealed promising results. Treatment
with crizotinib was associated with 62% of objective response rate in molecularly defined subgroup
of patients. Final conclusions are subject to further III phase clinical trials.
Get Citation

Keywords

non-small cell lung cancer; molecular targeted therapy; ALK kinase inhibitor; crizotinib

About this article
Title

Crizotinib — a new molecular targeted agent in the treatment of non-small-cell lung cancer

Journal

Oncology in Clinical Practice

Issue

Vol 8, No 5 (2012)

Article type

Review paper

Pages

193-203

Published online

2012-11-27

Bibliographic record

Onkol. Prak. Klin 2012;8(5):193-203.

Keywords

non-small cell lung cancer
molecular targeted therapy
ALK kinase inhibitor
crizotinib

Authors

Rafał Czyżykowski
Sylwia Dębska
Maja Habib
Magdalena Krakowska
Joanna Kubicka
Piotr Potemski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl